mAb-话题@MedSci

#mAb#

1302篇内容 | 2890人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912815, encodeId=a6fd19128158b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系, objectType=article, longId=300098, objectId=955d30009866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=955d30009866, replyNumber=0, likeNumber=74, createdTime=2022-05-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=955d30009866, moduleTitle=JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=955d30009866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912830, encodeId=89e719128303e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=61, createdTime=2022-11-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912797, encodeId=81d51912e97de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, objectType=article, longId=299023, objectId=2d572990238b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d572990238b, replyNumber=0, likeNumber=83, createdTime=2022-12-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d572990238b, moduleTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d572990238b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912761, encodeId=2b491912e6195, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=91, createdTime=2022-08-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912860, encodeId=29b21912860cd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS, objectType=article, longId=727477, objectId=0a19e27477f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a19e27477f4, replyNumber=0, likeNumber=54, createdTime=2023-02-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a19e27477f4, moduleTitle=J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a19e27477f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912731, encodeId=24be1912e31b2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析, objectType=article, longId=221468, objectId=b9382214685e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9382214685e, replyNumber=0, likeNumber=66, createdTime=2022-06-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9382214685e, moduleTitle=JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9382214685e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912799, encodeId=377c1912e99e3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, objectType=article, longId=299383, objectId=8ef92993836d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef92993836d, replyNumber=0, likeNumber=56, createdTime=2022-11-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef92993836d, moduleTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ef92993836d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912704, encodeId=f2d31912e0446, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Sotrovimab可降低新冠肺炎高风险人群病情进展风险, objectType=article, longId=219452, objectId=bce321945299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce321945299, replyNumber=0, likeNumber=51, createdTime=2022-01-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce321945299, moduleTitle=NEJM：Sotrovimab可降低新冠肺炎高风险人群病情进展风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce321945299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912708, encodeId=e9a91912e08ee, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=69, createdTime=2022-06-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912895, encodeId=84f51912895e6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, objectType=article, longId=737625, objectId=1396e376252d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1396e376252d, replyNumber=0, likeNumber=100, createdTime=2022-12-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1396e376252d, moduleTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1396e376252d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912723, encodeId=99de1912e236f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=67, createdTime=2022-10-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912870, encodeId=0a2619128e008, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究, objectType=article, longId=730107, objectId=dbcee30107b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbcee30107b2, replyNumber=0, likeNumber=70, createdTime=2022-11-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbcee30107b2, moduleTitle=Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbcee30107b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912736, encodeId=f86d1912e36ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究, objectType=article, longId=265038, objectId=9aa526503837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aa526503837, replyNumber=0, likeNumber=71, createdTime=2022-04-05, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aa526503837, moduleTitle=Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aa526503837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912768, encodeId=150c1912e6849, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, objectType=article, longId=294056, objectId=900f294056ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=900f294056ec, replyNumber=0, likeNumber=64, createdTime=2022-11-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=900f294056ec, moduleTitle=J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=900f294056ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912786, encodeId=348e1912e86a3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, objectType=article, longId=295365, objectId=755a295365ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=755a295365ca, replyNumber=0, likeNumber=74, createdTime=2022-05-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=755a295365ca, moduleTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=755a295365ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912733, encodeId=9eb11912e33b9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：TIGIT抗体Etigilimab±纳武单抗治疗晚期实体瘤, objectType=article, longId=221608, objectId=a1282216089b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1282216089b, replyNumber=0, likeNumber=65, createdTime=2022-05-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1282216089b, moduleTitle=Clin Cancer Res：TIGIT抗体Etigilimab±纳武单抗治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1282216089b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912750, encodeId=b5151912e50ad, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作, objectType=article, longId=292732, objectId=8da4292e32cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8da4292e32cb, replyNumber=0, likeNumber=75, createdTime=2022-06-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8da4292e32cb, moduleTitle=NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8da4292e32cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912825, encodeId=ef1b191282518, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Br J Dermatol：Suckinumab显示出对指甲型银屑病的高效和持久的疗效, objectType=article, longId=301222, objectId=6d8b30122242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d8b30122242, replyNumber=0, likeNumber=69, createdTime=2022-07-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d8b30122242, moduleTitle=Br J Dermatol：Suckinumab显示出对指甲型银屑病的高效和持久的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d8b30122242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912687, encodeId=72fa191268e4a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Neurology：纳他利珠单抗（natalizumab），治疗耐药性局灶性癫痫，有效性和安全性如何, objectType=article, longId=217327, objectId=aeb121e32747, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb121e32747, replyNumber=0, likeNumber=84, createdTime=2022-03-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb121e32747, moduleTitle=Neurology：纳他利珠单抗（natalizumab），治疗耐药性局灶性癫痫，有效性和安全性如何, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb121e32747)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912692, encodeId=f2df191269262, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, objectType=article, longId=217894, objectId=d2e921e89470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2e921e89470, replyNumber=0, likeNumber=106, createdTime=2022-01-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2e921e89470, moduleTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2e921e89470)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系

2022-05-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-11-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究

2022-12-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2022-08-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS

2023-02-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAAD：古塞库单抗（Guselkumab）连续五年治疗中度至重度银屑病的安全性分析

2022-06-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效

2022-11-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Sotrovimab可降低新冠肺炎高风险人群病情进展风险

2022-01-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-06-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较

2022-12-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2022-10-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究

2022-11-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Cancer Discov：Atezolizumab治疗高TMB肿瘤患者的疗效：MyPathway研究

2022-04-05

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Ibrutinib（伊布替尼）联合Rituximab（利妥昔单抗）治疗惰性套细胞淋巴瘤(IMCL-2015)的疗效

2022-11-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效

2022-05-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：TIGIT抗体Etigilimab±纳武单抗治疗晚期实体瘤

2022-05-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作

2022-06-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Br J Dermatol：Suckinumab显示出对指甲型银屑病的高效和持久的疗效

2022-07-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Neurology：纳他利珠单抗（natalizumab），治疗耐药性局灶性癫痫，有效性和安全性如何

2022-03-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究

2022-01-09

科室
- - 订阅+
  - 更多科室
工具
服务